W M Grady


Affiliation: Fred Hutchinson Cancer Research Center
Country: USA


  1. Shiovitz S, Bertagnolli M, Renfro L, Nam E, Foster N, Dzieciatkowski S, et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147:637-45 pubmed publisher
    ..Patients with stage III, CIMP-positive, MMR-intact colon tumors have longer survival times when irinotecan is added to combination therapy with fluorouracil and leucovorin. ..
  2. Grady W, Markowitz S. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci. 2015;60:762-72 pubmed publisher
    ..In this review, we will discuss our current understanding of the molecular pathogenesis of the polyp to cancer sequence and the potential to use this information to direct screening and prevention programs. ..
  3. Kaz A, Grady W, Stachler M, Bass A. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015;44:473-89 pubmed publisher
    ..Assays to detect molecular alterations associated with neoplastic progression could be used to improve the pathologic assessment of BE/EAC and to select high-risk patients for more intensive surveillance. ..
  4. Luo Y, Wong C, Kaz A, Dzieciatkowski S, Carter K, Morris S, et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology. 2014;147:418-29.e8 pubmed publisher
    ..Genome-wide alterations in DNA methylation occur during early stages of progression of tubular adenomas to cancer. These findings reveal heterogeneity in the pathogenesis of colorectal cancer, even at the adenoma step of the process. ..
  5. request reprint
    Grady W, Willis J, Trobridge P, Romero Gallo J, Munoz N, Olechnowicz J, et al. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer. 2006;118:600-8 pubmed
  6. request reprint
    Cui J, Cai Y, Hu Y, Huang Z, Luo Y, Kaz A, et al. Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation. Tumour Biol. 2016;37:12477-12483 pubmed
    ..In summary, our findings indicate that TPM2 appears to be commonly silenced by aberrant DNA methylation in colon cancer. TPM2 loss is associated with RhoA activation and tumor proliferation. ..